Temporal lobe epilepsy remains amongst the most common and drug refractory of
neurological disorders. Gene therapy may provide a realistic therapeutic approach …

Neuropeptide Y (NPY) is an endogenous peptide with powerful anticonvulsant properties. Its
overexpression in the rat hippocampus, mediated by the local application of recombinant …

Recombinant adeno‐associated viral (rAAV) vector‐induced neuropeptide Y (NPY)
overexpression in the hippocampus exerts powerful antiepileptic and antiepileptogenic …

Neuropeptide Y (NPY) inhibits seizures in experimental models and reduces excitability in
human epileptic tissue. We studied the effect of long-lasting NPY overexpression in the rat …

Evidence from studies in rodents and humans support an anti-seizure action of
neuropeptide Y (NPY) in focal, acquired epilepsy. However, the effects of NPY in …

Gene therapy may represent a promising alternative treatment of epileptic patients who are
resistant to conventional anti-epileptic drugs. Among the various approaches for the …

The anticonvulsive properties of neuropeptide Y (NPY) are opening up opportunity for the
development of NPY gene transfer as a therapy for epilepsy. In order to pursue the potential …

Functional studies in epileptic tissue indicate that neuropeptide Y and some of its peptide
analogs potently inhibit seizure activity. We investigated seizure susceptibility in transgenic …

Although novel treatment strategies based on the gene therapy approach for epilepsy has
been encouraging, there is still a gap in demonstrating a proof-of-concept in a clinically …

Gene therapy using recombinant adeno-associated viral vectors overexpressing
neuropeptide Y in the hippocampus exerts seizure-suppressant effects in rodent epilepsy …